BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

Roche’s deal to acquire a clinical cystic fibrosis program from U.K.-based Enterprise delivers a return to the biotech’s shareholders while allowing the venture-backed company to continue development of another pipeline project. Roche (SIX:ROG; OTCQX:RHHBY) is...
BioCentury | Jun 20, 2019
Distillery Techniques

TMEM16A as a marker for survival in pancreatic cancer

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers; gene profiling A study from Lily Yeh Jan and Yuh Nung Jan at UCSF suggests that tumor levels of TMEM16A could help predict survival in pancreatic cancer patients, and...
BioCentury | Mar 1, 2019
Company News

Sarepta acquires Myonexus, reports LGMD trial results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed...
BioCentury | Feb 27, 2019
Company News

On strength of first LGMD data, Sarepta exercises option to buy Myonexus

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed...
BioCentury | Apr 13, 2018
Financial News

Enterprise raises £29M series B

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) on April 12 in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and...
BioCentury | Apr 12, 2018
Financial News

Versant, Novartis Venture lead £29M round for Enterprise

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and existing investors Epidarex...
BioCentury | Apr 12, 2018
Finance

Enterprise engages

Enterprise Therapeutics Ltd.’s belief that it can improve on existing mucus-clearing therapies led an investor syndicate to back the respiratory company in a £29 million ($40.9 million) series B round. Versant Ventures and Novartis Venture...
BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Cystic fibrosis (CF) Cell culture, patient sample and mouse studies suggest inhibiting the interaction of miR-9 with its negative regulator ANO1 could help treat mucus accumulation in CF. In bronchial epithelial cells from patients,...
BioCentury | Apr 13, 2017
Targets & Mechanisms

Cool and also collected

A Nature Medicine study published this week shows the immune-modulating peptide thymosin α1 provides unexpected improvements in the dysfunctional ion channel that causes cystic fibrosis, and could lead to a single agent therapy to compete...
Items per page:
1 - 10 of 32